Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9375
Title: Hepatocellular carcinoma and chemoembolization.
Austin Authors: Harris, M;Gibbs, P;Cebon, Jonathan S ;Jones, R ;Sewell, Richard B;Schelleman, Tony;Angus, Peter W 
Affiliation: Department of Medical Oncology, Austin & Repatriation Medical Centre, Melbourne, Victoria, Australia
marion.harris@ludwig.edu.au
Issue Date: 1-Dec-2001
Publication information: Internal Medicine Journal; 31(9): 517-22
Abstract: Chemoembolization is often used in the treatment of hepatocellular carcinoma; however, there are limited data on its efficacy in an Australian setting.To review retrospectively the experience of 21 patients with hepatocellular carcinoma who collectively had 36 chemoembolizations performed between October 1995 and February 1999 in a teaching hospital and liver transplant centre in Victoria.Selective catheterization of the right or left hepatic arteries was performed. A mixture of cisplatin 50 mg, epirubicin 50 mg, mitomycin C 10 mg, Lipiodol and gelfoam was injected. Computed tomography (CT) scans were performed at baseline and at 1-3 months after chemoembolization. Outcome measures included response rates, toxicity, progression-free and overall survival.CT response rates: partial response 19% (n = 7), median duration 11 months (range 2+ to 37+); minor response 17% (n = 6), median duration 7 months (1+ to 12+); stable disease 42% (n = 15), median duration 3 months (1+ to 15 months); and progressive disease 22% (n = 8). Major toxicities included one case each of acute renal failure, contrast encephalopathy, gastric ulceration and hepatorenal failure. Median progression-free survival was 3 months (range 0-37+). Median overall survival was 15 months (range 6-50+).Chemoembolization has a role in the palliative treatment of hepatocellular carcinoma. Our response rates and toxicity data are consistent with those in the published literature. However, new treatments are needed and prevention of disease by reduction in the prevalence of chronic hepatitis B and C will be required to significantly reduce mortality from this tumour.
Gov't Doc #: 11767865
URI: http://ahro.austin.org.au/austinjspui/handle/1/9375
URL: https://pubmed.ncbi.nlm.nih.gov/11767865
Type: Journal Article
Subjects: Adult
Aged
Carcinoma, Hepatocellular.therapy
Chemoembolization, Therapeutic.adverse effects.methods
Disease-Free Survival
Female
Humans
Liver Neoplasms.therapy
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Dec 8, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.